EC Healthcare Chairman Mr. Eddy Tang increases his shareholding, demonstrating his full confidence in the future development of the group


HONG KONG, September 2, 2022 – (ACN Newswire) – – EC Health (the “Company”, which together with its subsidiaries is referred to as the “Group”, stock code SEHK: 2138), the largest non-hospital medical group in hong kong*, is pleased to announce that the September 1, 2022the Chairman, Managing Director and Chief Executive Officer of the Group Mr. Tang Chi Fai acquired a total of 107,000 Company shares on the open market for approximately HK$587,000 at an average price of HK$5.4905 per share. After the deal, Mr. Tang holds a total of 722,034,610 shares of the Company, increasing its equity interest from 61.26% to 61.27%.

Mr. Eddy TangChairman, Managing Director and Chief Executive Officer of EC Health said: “Benefiting from the result of its continuous investments in IT, brand and service, the Group recorded a sales volume of no less than HK$860 million in the first quarter of the financial year ended March 31, 2023 (April to June 2022). This shows a good recovery of its activity. EC Health will continue to consolidate the healthcare market through organic growth and acquisitions and thus strengthen its leading position in the market. The Group believes that the medical market will remain resilient in a difficult economic environment and that public-private partnerships in healthcare will continue to drive spending in the medical market. that of Hong Kong long-term private health sector. Looking to the future, management remains optimistic about the progress of the Group’s business. The Group will also continue its in-depth cooperation with key players in technology, telecommunications, insurance, real estate and pharmaceuticals in order to continue to enrich EC Healthcare closed healthcare ecosystem. »

About EC Health

EC Health is that of Hong Kong leading provider of non-hospital medical services*, relying on its core businesses of preventive and precision medicine, and committed to the development of medical artificial intelligence by integrating its multidisciplinary medical services. This decision, which is based on the Group’s high-end brand image and quality customer services, aims to provide customers with safe and efficient healthcare and medical services with professionalism.

The Group mainly engages in the provision of one-stop medical and healthcare services in Greater China. The Group provides a full range of services and products under its well-known brands, including those of its one-stop provider of aesthetic medical solutions DR REBORN which ranked first in hong kong by sales for years, primary care clinics established jointly with Tencent Doctorate, New York Spine and Physiotherapy Center NYMG Chiropractic Services Center, re:HEALTH Health Management Center, Hong Kong Professional Vaccine HKPV, EC DENTAL CARE Comprehensive Dental Center, Diagnostic and Imaging Center HKAI, a reVIVE oncology treatment center, a day procedure center HKMED, a specialist clinic SPECIALIST CENTER, NEW MEDICAL CENTER and Prime Medical Centers, specialist in obstetrics and gynecology ZENITH MEDICAL CENTER AND PRENATAL DIAGNOSIS CENTER, specialist center, a PRIME CARE pediatric center, cardiology center HONG KONG INTERNATIONAL CARDIOLOGY CENTER, PathLab Medical Laboratoriesa professional hair care center HAIR FOREST, VIVID EYE ophthalmology center and CE Veterinary Hospital and imaging center.

*According to an independent study conducted by Frost and Sullivan in terms of turnover in 2020 and 2021

For more information, please contact:

iPR Ogilvy Limited

Callis Lau / Lorraine Luk / Charmaine IP

Tel: (852) 2136 6952 / 2169 0467 / 3920 7649

Fax: (852) 3170 6606


Copyright 2022 ACN Newswire. All rights reserved.

© Japan Corporate News, source JCN Press Releases


Comments are closed.